Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndromestrategies for in vivo administration: Part-II

doi:10.3390/jcm8091332

Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/61704

Registo completo

Campo DC	Valor	Idioma
dc.contributor.author	Vieira, Raquel	por
dc.contributor.author	Souto, Selma B.	por
dc.contributor.author	Sánchez-López, Elena	por
dc.contributor.author	López Machado, Ana	por
dc.contributor.author	Severino, Patricia	por
dc.contributor.author	Jose, Sajan	por
dc.contributor.author	Santini, Antonello	por
dc.contributor.author	Silva, Amelia M.	por
dc.contributor.author	Fortuna, Ana	por
dc.contributor.author	García, Maria Luisa	por
dc.contributor.author	Souto, Eliana B.	por
dc.date.accessioned	2019-10-10T15:31:46Z	-
dc.date.available	2019-10-10T15:31:46Z	-
dc.date.issued	2019-08-28	-
dc.identifier.citation	Vieira, Raquel; Souto, Selma B.; Sánchez-López, Elena; López Machado, Ana; Severino, Patricia; Jose, Sajan; Santini, Antonello; Silva, Amelia M.; Fortuna, Ana; García, Maria Luisa; Souto, Eliana, Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndromestrategies for in vivo administration: Part-II. Journal of Clinical Medicine, 8(9), 1332, 2019	por
dc.identifier.issn	2077-0383	por
dc.identifier.uri	https://hdl.handle.net/1822/61704	-
dc.description.abstract	Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic ß-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.	por
dc.description.sponsorship	The authors acknowledge the financial support received from Portuguese Science and TechnologyFoundation (FCT/MCT) and from European Funds (PRODER/COMPETE) under the project referenceM-ERA-NET/0004/2015-PAIRED, co-financed by FEDER, under the Partnership Agreement PT2020. The authors also acknowledge the support of the Institute of Nanoscience and Nanotechnology under the project ART (2018).	por
dc.language.iso	eng	por
dc.publisher	Multidisciplinary Digital Publishing Institute (MDPI)	por
dc.rights	openAccess	por
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	por
dc.subject	diabetes mellitus	por
dc.subject	animal models	por
dc.subject	in vivo	por
dc.subject	administration routes	por
dc.title	Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndromestrategies for in vivo administration: Part-II	por
dc.type	article	-
dc.peerreviewed	yes	por
dc.relation.publisherversion	https://www.mdpi.com/journal/jcm	por
dc.comments	CEB52044	por
oaire.citationIssue	9	por
oaire.citationVolume	8	por
dc.date.updated	2019-10-07T11:10:31Z	-
dc.identifier.eissn	2077-0383	por
dc.identifier.doi	10.3390/jcm8091332	por
dc.description.publicationversion	info:eu-repo/semantics/publishedVersion	-
dc.subject.wos	Science & Technology	por
sdum.journal	Journal of Clinical Medicine	por
oaire.version	VoR	por
Aparece nas coleções:	CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series